International Journal of Surgical Oncology

Research Article

Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

Table 3

Relevant study population characteristics.


Patient ID	Primary tumor site	Highest FIGO stage	Staging		No. of NACT cycles	NACT response	No. of ASC cycles	Recurrence			Disease status	Time to recurrence (months)	Overall follow-up (months)
Patient ID	Primary tumor site	Highest FIGO stage	Clinical (cTNM)	Post-NACT and CRS/HIPEC (ypTNM)	No. of NACT cycles	NACT response	No. of ASC cycles	Intracavitary	Lymph nodes	Distant	Disease status	Time to recurrence (months)	Overall follow-up (months)

1	OV	IIIC	cT3c cN0 cM0	ypT3c ypN1 cM0	4	PD	2	—	R-iliac LN	—	DOD	13.75	24.61
2	PP	IVB	cT3c cN1 cM1b	ypT3c ypN1 cM1b	6	PD	NA	—	—	—	DOC	—	3.29
3	OV	IVA	cT3c cN1 pM1a	ypT3c ypN0 pM1a	3	Non-CR/non-PD	3	—	Portacaval LN	—	AWD	37.66	56.35
4	PP	IVA	cT3c cN1 pM1a	ypT3c ypN1 pM1a	4	Non-CR/non-PD	2	Loculated ascites, L-abdomen thickening	—	—	DOD	15.99	51.18
5	OV	IVA	cT3c cN0 pM1a	ypT3c ypN0 pM1a	3	PD	3	Pancreatic and L-abdomen implants	—	R-major and minor lung fissures thickening	DOD	7.93	20.43
6	OV	IIIC	cT3c cN0 cM0	ypT3b ypN0 cM0	3	Non-CR/non-PD	3	Mass adjacent to spleen, L-paramedian mass, L-external iliac nodule	—	—	DOD	12.43	45.63
7	OV	IVB	cT3c cN0 pM1a	ypT3c ypN1a pM1b	4	SD	4	Mesenteric and anterior abdominal wall nodules	L-external iliac LN	Hepatic metastases	AWD	18.13	45.16
8	PP	IIIC	cT3c cN0 cM0	ypT3c ypN0 cM0	3	PR	3	—	Para-aortic LN	Internal mammary LN	DOD	12.40	32.47
9	FT	IIIC	cT3c cN0 cM0	ypT3c ypN1 cM0	3	PR	3	Ascites and small peritoneal nodules	—	—	DOD	11.78	18.13
10	PP	IIIC	cT3c cN1 cM0	ypT0 ypN1a cM0	3	Non-CR/non-PD	3	Bilateral pelvic sidewall adenopathy	R-iliac and presacral LNs, L-para-aortic and retrocaval LNs	—	DOD	11.71	25.33
11	FT	IIIC	cT3c cN0 cM0	ypT3c ypN1a cM0	3	Non-CR/non-PD	3	Ascites and mesenteric enhancement	—	—	DOD	9.97	24.38
12	FT	IIIC	cT3c cN0 cM0	ypT3c ypN1a cM0	3	Non-CR/non-PD	3	—	Aortocaval, anterior aortic, L-para-aortic and aortic bifurcation LNs	—	AWD	10.86	34.24
13	FT	IVB	cT3c cN0 cM0	ypT3b ypN0 pM1b	3	CR	3	—	L-pelvic LN, LLQ and mid abdomen LNs	—	NED	19.14	33.06
14	FT	IVB	cT3c cN0 cM0	ypT3c ypN1a pM1b	4	PD	NA	—	—	R-pleural effusion, R-cardiophrenic and epicardial LN	DOD	6.71	33.09
15	FT	IIIC	cT3c cN0 cM0	ypT3c ypN0 cM0	3	SD	3	LUQ peritoneal nodule	—	L-epicardial LN	AWD	13.78	31.02
16	PP	IIIC	cT3c cN1 cM0	ypT3c ypN1 cM0	3	SD	NA	Presacral and perirectal densities, porta hepatis thickening, descending and sigmoid colon implants	R-pelvic LN, aortic bifurcation and anterior R-iliac LNs	Two small liver lesions	DOD	8.22	20.53
17	PP	IVB	cT3c cN0 cM1b	ypT3a ypN0 cM1b	4	PR	4	—	LN anterior to the 2^nd portion of the dueodenum	—	NED	29.54	29.80
18	PP	IIIC	cT3c cN1 cM0	ypT3a ypN0 cM0	4	Non-CR/non-PD	3	—	—	—	NED	—	25.30
19	FT	IVB	cT3c cN0 cM0	ypT3c ypN1 pM1b	3	Non-CR/non-PD	3	—	—	—	NED	—	21.35
20	OV	IIIC	cT3c cN1 cM0	ypT3c ypN1a cM0	3	SD	3	Cecal thickening	Posterior aortic and aortocaval LNs, R-pelvic LN	—	AWD	9.57	22.83
21	OV	IIIC	cT3c cN0 cM0	ypT0 ypN0 cM0	4	CR	2	—	—	—	NED	—	22.07
22	OV	IVB	cT3c cN1 cM1b	ypT3c ypN1b pM1a	3	SD	3	—	Para-aortic and aortocaval LNs	L-supraclavicular LN	AWD	10.10	19.80
23	FT	IVB	cT3c cN1 cM0	ypT3c ypN0 pM1b	3	SD	3	Cecal and anterior pancreatic nodules	—	—	AWD	9.87	18.68
24	OV	IVB	cT3c cN1 cM1b	ypT2a ypN1a cM1b	3	PR	3	LUQ peritoneal nodules	L-iliac LN	—	AWD	11.55	18.39
25	FT	IVA	cT3c cN0 pM1a	ypT3c ypN1a pM1a	6	Non-CR/non-PD	NA	—	—	—	NED	—	13.13
26	FT	IVB	cT3c cN1 cM1b	ypT2b ypN0 pM1a	6	CR	NA	—	R-inguinal, R-para-aortic and multiple bilateral retroperitoneal LNs	L-supraclavicular, R-paratracheal, R-axillary, pretracheal and R-prehilar LNs	DOD	3.36	11.41
27	FT	IVB	cT3c cN1 pM1b	ypT3a ypN0 pM1b	6	CR	NA	—	Multiples retroperitoneal and pelvic LN	—	AWD	9.11	19.31

^aAccording to the 8th edition of the American Joint Committee on Cancer TNM staging system, and ^baccording to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; AWD: alive with disease, CC-Score: completeness of cytoreduction score, CR: complete response, DOC: dead of other cause, DOD: dead of disease, FT: fallopian tube, L: left, LNs: lymph nodes, LUQ: left upper quadrant, NA: not applicable, NACT: neoadjuvant systemic chemotherapy, NED: no evidence of disease, OV: ovarian, PD: progressive disease, PP: primary peritoneal, PR: partial response, R: right, and SD: stable disease